Efficacy of dupilumab therapy in three children with refractory eosinophilic esophagitis: Case study
Annales Academiae Medicae Silesiensis · 19.06.2026
DOI: 10.18794/aams/222159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Academiae Medicae Silesiensis, online erschienen am 19.06.2026. Verfasst von Katarzyna Górowska-Kowolik und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Eosinophilic esophagitis (EoE) is an inflammatory chronic disease of esophagus, that contributes to symptoms of esophagus dysfunction. Recommended treatment strategies to obtain EoE resolution range from elimination diets, through proton pump inhibitors, to topical corticosteroids. In 2023 European Medicines Agency firstly approved the use of dupilumab, which currently is recommended for children from 1 year of age and weighing 15 kg, who cannot take conventional treatment or for whom the therapy is insufficient. We present cases of refractory to conventional therapies patients for whom dupilumab led to endoscopic, histologic and finally clinical remission.
Zitieren
APA
Górowska-Kowolik, K., Kłaczka-Sobków, D., Sobków, P., & Kwiecień, J. (2026). Efficacy of dupilumab therapy in three children with refractory eosinophilic esophagitis: Case study. Annales Academiae Medicae Silesiensis. https://doi.org/10.18794/aams/222159
Vancouver
Górowska-Kowolik K, Kłaczka-Sobków D, Sobków P, Kwiecień J. Efficacy of dupilumab therapy in three children with refractory eosinophilic esophagitis: Case study. Annales Academiae Medicae Silesiensis. 2026. doi:10.18794/aams/222159
BibTeX
@article{GrowskaKowolik2026,
author = {Górowska-Kowolik, Katarzyna and Kłaczka-Sobków, Daria and Sobków, Piotr and Kwiecień, Jarosław},
title = {Efficacy of dupilumab therapy in three children with refractory eosinophilic esophagitis: Case study},
journal = {Annales Academiae Medicae Silesiensis},
year = {2026},
doi = {10.18794/aams/222159}
}
EUVIMED